Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue

Molecular Pharmacology

Volumn 69, Issue 3, 2006, Pages 908-920

  Chouinard, Sarah ^b   Tessier, Ḿelanie ^b   Vernouillet, Gabrielle ^a   Gauthier, Sylvain ^d   Labrie, Fernand ^b   Barbier, Olivier ^a   B́elanger, Alain ^b,c  

^a Université Laval   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTRADIOL DERIVATIVE; ESTROGEN DERIVATIVE; FULVESTRANT; FULVESTRANT 17 GLUCURONIDE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A1; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CHROMATOGRAPHY; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG STRUCTURE; GLUCURONIDATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST; CELLS, CULTURED; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; ILEUM; JEJUNUM; LIVER;

EID: 33644845228     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.015891     Document Type: Article

References (39)

1. Albert C, Vallee M, Beaudry G, Belanger A, and Hum DW (1999) The monkey and human uridine diphosphate-glucuronosyltransferase UGT1A9, expressed in steroid target tissues, are estrogen-conjugating enzymes. Endocrinology 140:3292-3302.
2. Armstrong SC and Cozza KL (2003) Pharmacokinetic drug interactions of morphine, codeine and their derivatives: theory and clinical reality, part II. Psychosomatics 44:515-520.
3. Barbier O, Albert C, Martineau I, Vallee M, High K, Labrie F, Hum DW, Labrie C, and Belanger A (2001) Glucuronidation of the nonsteroidal antiestrogen EM-652 (SCH 57068), by human and monkey steroid conjugating UDP-glucuronosyltransferase enzymes. Mol Pharmacol 59:636-645.
4. Belanger A, Pelletier G, Labrie F, Barbier O, and Chouinard S (2003) Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends Endocrinol Metab 14:473-479.
5. Bross PF, Cohen MH, Williams GA, and Pazdur R (2002) FDA drug approval summaries: fulvestrant. Oncologist 7:477-480.
6. Burchell B, Soars M, Monaghan G, Cassidy A, Smith D, and Ethell B (2000) Drug-mediated toxicity caused by genetic deficiency of UDP- glucuronosyltransferases. Toxicol Lett 112-113:333-340.
7. Cai Y, Luo Q, Sun M, and Corke H (2004) Antioxidant activity and phenolic compounds of 112 traditional Chinese medicinal plants associated with anticancer. Life Sci 74:2157-2184.
8. Cheng Z, Radominska-Pandya A, and Tephly TR (1999) Studies on the substrate specificity of human intestinal UDP-glucuronosyltransferases 1A8 and 1A10. Drug Metab Dispos 27:1165-1170.
9. Coffman BL, Rios GR, King CD, and Tephly TR (1997) Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 25:1-4.
10. Desai AA, Innocenti F, and Ratain MJ (2003) UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics 13:517-523.
11. Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, and Guillemette C (2002) Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62:608-617.
12. Gong QH, Cho JW, Huang T, Potter C, Gholami N, Basu NK, Kubota S, Carvalho S, Pennington MW, Owens IS, et al. (2001) Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 11:357-368.
13. Green MD, King CD, Mojarrabi B, Mackenzie PI, and Tephly TR (1998) Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos 26:507-512.
14. Guillemette C, Belanger A, and Lepine J (2004) Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview. Breast Cancer Res 6:246-254.
15. Guillemette C, Ritter JK, Auyeung DJ, Kessler FK, and Housman DE (2000) Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 10:629-644.
16. Howell SJ, Johnston SR, and Howell A (2004) The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract Res Clin Endocrinol Metab 18:47-66.
17. Iwai M, Maruo Y, Ito M, Yamamoto K, Sato H, and Takeuchi Y (2004) Six novel UDP-glucuronosyltransferase (UGT1A3) polymorphisms with varying activity. J Hum Genet 49:123-128.
18. Jedlitschky G, Cassidy AJ, Sales M, Pratt N, and Burchell B (1999) Cloning and characterization of a novel human olfactory UDP- glucuronosyltransferase. Biochem J 340 (Pt 3):837-843.
19. Kemp DC, Fan PW, and Stevens JC (2002) Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30:694-700.
20. Lazard D, Zupko K, Poria Y, Nef P, Lazarovits J, Horn S, Khen M, and Lancet D (1991) Odorant signal termination by olfactory UDP glucuronosyl transferase. Nature (Lond) 349:790-793.
21. Lepine J, Bernard O, Plante M, Tetu B, Pelletier G, Labrie F, Belanger A, and Guillemette C (2004) Specificity and regioselectivity of the conjugation of estradiol, estrone and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab 89:5222-5232.
22. Levesque E, Beaulieu M, Hum DW, and Belanger A (1999) Characterization and substrate specificity of UGT2B4 (E458): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 9:207-216.
23. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A, Fournel-Gigleux S, Green M, Hum DW, Iyanagi T, et al. (1997) The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7:255-269.
24. Miners JO, Smith PA, Sorich MJ, McKinnon RA, and Mackenzie PI (2004) Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44:1-25.
25. Nishiyama T, Ogura K, Nakano H, Ohnuma T, Kaku T, Hiratsuka A, Muro K, and Watabe T (2002) Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol 63:1817-1830.
26. Robertson JF and Harrison M (2004) Fulvestrant: pharmacokinetics and pharmacology. Br J Cancer 90 (Suppl 1):S7-10.
27. Robertson JF, Nicholson RI, Bundred NJ, Anderson E, Rayter Z, Dowsett M, Fox JN, Gee JM, Webster A, Wakeling AE, et al. (2001) Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) -nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 61:6739-6746.
28. Sabolovic N, Heydel JM, Li X, Little JM, Humbert AC, Radominska-Pandya A, and Magdalou J (2004) Carboxyl nonsteroidal anti-inflammatory drugs are efficiently glucuronidated by microsomes of the human gastrointestinal tract. Biochim Biophys Acta 1675:120-129.
29. Soars MG, Ring BJ, and Wrighton SA (2003) The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases. Drug Metab Dispos 31:762-767.
30. Strassburg CP, Manns MP, and Tukey RH (1998) Expression of the UDP-glucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extrahepatic UGT1A8. J Biol Chem 273:8719-8726.
31. Strassburg CP, Strassburg A, Kneip S, Barut A, Tukey RH, Rodeck B, and Manns MP (2002) Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 50:259-265.
32. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression and disease. Annu Rev Pharmacol Toxicol 40:581-616.
33. Turgeon D, Carrier JS, Chouinard S, and Belanger A (2003a) Glucuronidation activity of the UGT2B17 enzyme toward xenobiotics. Drug Metab Dispos 31:670-676.
34. Turgeon D, Carrier JS, Levesque E, Beatty BG, Belanger A, and Hum DW (2000) Isolation and characterization of the human UGT2B15 gene, localized within a cluster of UGT2B genes and pseudogenes on chromosome 4. J Mol Biol 295:489-504.
35. Turgeon D, Chouinard S, Belanger P, Picard S, Labbe JF, Borgeat P, and Belanger A (2003b) Glucuronidation of arachidonic and linoleic acid metabolites by human UDP-glucuronosyltransferases. J Lipid Res 44:1182-1191.
36. van Heek M, Farley C, Compton DS, Hoos L, Alton KB, Sybertz EJ, and Davis HR Jr (2000) Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235 and its glucuronide, SCH60663. Br J Pharmacol 129:1748-1754.
37. Venkatakrishnan K, Schmider J, Harmatz JS, Ehrenberg BL, von Moltke LL, Graf JA, Mertzanis P, Corbett KE, Rodriguez MC, Shader RI, et al. (2001) Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. J Clin Pharmacol 41:1043-1054.
38. Villeneuve L, Girard H, Fortier LC, Gagne JF, and Guillemette C (2003) Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 307:117-128.
39. Wakeling AE, Dukes M, and Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867-3873.